Miscellaneous musculoskeletal disorders:

Indications for: VOXZOGO

To increase linear growth in children with achondroplasia and open epiphyses.

Adult Dosage:

Not applicable.

Children Dosage:

<5yrs: not established. Give by SC inj once daily (at same time each day) into middle of thighs, lower abdominal area, buttocks, or upper arms; rotate inj sites. Base dose on actual body weight. ≥5yrs (10–11kg): 0.24mg; (12–16kg): 0.28mg; (17–21kg): 0.32mg; (22–32kg): 0.4mg; (33–43kg): 0.5mg; (44–59kg): 0.6mg; (60–89kg): 0.7mg; (≥90kg): 0.8mg.

VOXZOGO Warnings/Precautions:

Risk of transient decreases in BP. Ensure adequate food and fluid intake (~240–300mL) prior to initiation. Monitor body weight, growth, physical development regularly every 3–6 months. Permanently discontinue if no further growth potential due to closure of epiphyses. Renal impairment (eGFR <60mL/min/1.73m2): not recommended. Pregnancy. Nursing mothers.

VOXZOGO Classification:

Human C type natriuretic peptide (CNP) analog.

Adverse Reactions:

Inj site reactions (erythema, swelling, urticaria), vomiting, arthralgia, decreased BP, gastroenteritis, diarrhea, dizziness, ear pain, influenza.

Generic Drug Availability:


How Supplied:

Single-dose vials (2mL)—10 (w. prefilled diluent syringes, needles, syringes)